1. An elevated lipoprotein(a) plasma level as a cardiovascular risk factor. (May 2015) Authors: Tselmin, S.; Müller, G.; Gelgaft, E.; Fischer, S.; Julius, U. Journal: Atherosclerosis Issue: Volume 18(2015) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Asymmetric dimethylarginine (ADMA) mediates the effect of miRNA-762 on all-cause mortality in patients with coronary artery disease (CAD). (August 2021) Authors: Tselmin, S.; Kleber, M.; Jarzebska, N.; März, W.; Jin, H.; Bornstein, S.R.; Mangoni, A.; Rodionov, R.N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Asymmetric dimethylarginine (ADMA) mediates the effect of miRNA-762 on all-cause mortality in patients with coronary artery disease. (August 2022) Authors: Jarzebska, N.; Tselmin, S.; Kleber, M.E.; Maerz, W.; Jin, H.; Bornstein, S.; Mangoni, A.; Weiss, N.; Rodionov, R. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cardiovascular events in patients treated by lipoprotein apheresis (LA) – Analysis of possible reasons. (September 2016) Authors: Tselmin, S.; Fischer, S.; Pistrosch, F.; Müller, G.; Julius, U. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Elevated lipoprotein(a) levels result in a high cardiovascular risk – A prospective analysis of a lipidology outpatients unit. (September 2016) Authors: Schatz, U.; Fischer, S.; Julius, U.; Bornstein, S.R.; Tselmin, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Homoarginine supplementation in patients with heart failure with preserved ejection fraction (HFpEF). Protocol of multicentre randomized controlled trial. (December 2020) Authors: Tselmin, S.; Jarzebska, N.; Rodionov, R.; Schwedhelm, E. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Hypertriglyceridemia in an outpatient department – Significance as an atherosclerotic risk factor. (May 2015) Authors: Scholz, M.; Tselmin, S.; Fischer, S.; Julius, U. Journal: Atherosclerosis Issue: Volume 18(2015) Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. (November 2017) Authors: Tselmin, S.; Müller, G.; Schatz, U.; Julius, U.; Bornstein, S.R.; Hohenstein, B. Journal: Atherosclerosis Issue: Volume 30(2017) Page Start: 209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lipoprotein apheresis influences monocyte subpopulations. (November 2017) Authors: Jellinghaus, S.; Reich, C.; Schatz, U.; Tselmin, S.; Ibrahim, K.; Pfluecke, C.; Schauer, A.; Bornstein, S.R.; Hohenstein, B.; Strasser, R.H.; Julius, U.; Poitz, D.M. Journal: Atherosclerosis Issue: Volume 30(2017) Page Start: 108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study. (November 2017) Authors: Schatz, U.; Tselmin, S.; Müller, G.; Julius, U.; Hohenstein, B.; Fischer, S.; Bornstein, S.R. Journal: Atherosclerosis Issue: Volume 30(2017) Page Start: 246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗